Navigation Links
Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
Date:11/4/2010

3 (the "Registration Statement") (including prospectus) for the offering of Common Shares to which this communication relates shortly after the Record Date.  Non-registered beneficial shareholders are advised to contact their broker, investment dealer or other financial intermediary for details on how to participate in the Plan.  To participate in the Plan, eligible shareholders must return their enrollment forms to the Agent in accordance with the Plan by 5:00 p.m. (Toronto time) on December 8, 2010.

This press release does not and will not constitute an offer to sell or the solicitation of an offer to buy Common Shares.  Valeant intends to file a Registration Statement (including a prospectus) with the Securities and Exchange Commission (the "SEC") for the offering of Common Shares to which this communication relates.  Before investing, eligible shareholders should read the prospectus in that Registration Statement and other documents Valeant has filed with the SEC and with the Canadian Securities Administrators (the "CSA") for more complete information about Valeant and the offering.  These documents may be obtained, free of charge, at the website maintained by the SEC at www.sec.gov and on SEDAR at www.sedar.com.  These documents may also be obtained, free of charge, from Valeant's website (www.valeant.com) under the tab "Investor Relations" and then under the heading "SEC Filings," or by directing a request to Valeant, 7150 Mississauga Road, Mississauga, Ontario, Canada, L5N 8M5, Attention: Investor Relations.  Additionally, these documents will be available from the Agent after the Record Date.  The Agent can be reached at 1-800-387-0825.  This press release is being issued pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended.

Important Income-Tax Information f
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
2. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
3. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
4. Valeant and Biovail Announce Results of Special Meetings of Shareholders
5. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
6. Valeant to Acquire Polish Products
7. Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
8. Techne Corporation Declares Dividend
9. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Lilly Declares Fourth-Quarter 2010 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... Calif. , July 28, 2014 ... leader in lifestyle healthcare and subsidiary ... that it has acquired Physician Recommended Nutriceuticals (PRN) ... omega-3s, and related products for dry ... Plymouth Meeting, PA, in a transaction worth up ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3
... guide low-income,and minority cancer patients through cancer treatment, ... major obstacles that prevent them,from receiving quality care ... October 28, 2007, at the American Society for ... Angeles. Minority and low-income cancer patients continue ...
... FLUSHING, N.Y., Oct. 30 The following is,being issued by New York Hospital Queens:, ... aureus(MRSA) is scheduled for ... James Rahal, M.D., and a team of infectious disease ... will address the ...
Cached Medicine Technology:Patient Navigators Help Minority, Low-Income Cancer Patients Get Life-Saving Treatments 2Hospital to Hold MRSA Briefing for Media and Community Leaders 2
(Date:7/28/2014)... 28, 2014 Ticket Down is ... Champions Cup Match between Manchester City and Liverpool FC ... Bronx has hosted countless big events since it opened several ... of the original Yankee Stadium, however, it has been a ... City metro area. , The Yankees Stadium is the ...
(Date:7/28/2014)... 2014 A January 2013 study ... intake in those who were self-diagnosed gluten-intolerant yielded little ... nutrition for San Diego health and wellness retreat ... for those who are unclear about the role gluten ... is a protein, found in wheat, barley, rye, and ...
(Date:7/28/2014)... Dawn Echols’ professional background spans ... music. This experience has honed her people skills ... Her professional counseling ( http://dawningphoenix.com ) work includes ... offenders in domestic violence. , As owner ... enjoys counseling individuals and groups for a variety ...
(Date:7/28/2014)... 28, 2014 Ticket Down is ... tickets in Dallas, TX at the Cotton Bowl. The ... the USA and it is an eight team tourney. ... world including teams from La Liga, Serie A, English Premier ... battle it out on the pitch include: Manchester United, ...
(Date:7/28/2014)... Massachusetts (PRWEB) July 28, 2014 ... Summit Provider Exchange technology solution in ... integration efforts and support collaboration with their New ... bed acute-care medical center located in New Jersey, ... seasonal visitors with a variety of inpatient and ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3
... ... RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst’s clients in ... ... 44th Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists in ...
... , ATLANTA, Dec. 7 Results of two ... the antiepileptic drug (AED) Vimpat® for patients requiring add-on therapy ... feasible. These data, which were presented by UCB at ... Boston, further clarify the role of intravenous Vimpat in the ...
... , , NEW ORLEANS, Dec. 7 ... developing novel, proprietary antibodies for the treatment of cancer, ... a poster(1) with new data from its ongoing phase ... patients with non-Hodgkin,s lymphoma (NHL) at the 51ST Annual ...
... , MIAMI, Dec. 7 A couple years ... searching frantically for gifts made in the USA. This fall, ... toys are suspect. Renowned parenting expert Dr. Jeffrey Fine, Ph.D., ... retarding language development and shortening attention spans. Moreover, there is ...
... ... chairman of the board of directors for PerfectServe, a clinical communications company currently serving ... ... Gene Barduson was recently named executive chairman of the board of directors for ...
... , WEST PALM BEACH, Fla., Dec. 7 The ... to publicize the first major innovation in hospital privacy ... is already saving hospitals millions in maintenance costs. , ... Record to elevate Cubicle Curtain Factory,s profile in print, broadcast, ...
Cached Medicine News:Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 2Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 3Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 4Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 5Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 2Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 3Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 4Health News:Top 10 Toys That Will Scar Your Child for Life 2Health News:Gene Barduson Named Chairman of PerfectServe Board of Directors 2Health News:Cubicle Curtain Factory Retains TransMedia Group to Promote First Privacy Curtain to Reduce Hospital Maintenance Cost 2
... Simple, cost-effective microfiltration for your transfusion ... also brings you an easy and ... of microfiltration for a variety of ... postoperative applications, autologous or homologous transfusions, ...
This high technology cast plaster cutter saw is very easy and comfortable to use....
... Designed to reduce noise to a minimum ... and less hearing trauma for the clinician. ... high power in a smaller, lighter package. ... saw's balance and ergonomics for more user ...
The True/Fix Cannulated Bone Screw System contains 7.0mm large cannulated bone screws and 3.5mm cortical and 4.0mm cannulated cancellous bone screws....
Medicine Products: